Teva downplays Copaxone copying as sales rise

As Teva Pharmaceutical Industries (NASDAQ: TEVA) Q2 results got a big boost from growing Copaxone sales, executives are saying they're confident that generic knock-offs of the multiple sclerosis drug won't be forthcoming anytime soon. Report | Report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.